BD's outgoing diagnostic solutions and biosciences catalog brought in about $3.4 billion in 2024 sales. It will include tests for infectious disease and cervical cancer screening, as well as flow ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced better-than-expected revenue in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 ...

Waters plans to combine with the Biosciences & Diagnostic Solutions business of BD (Becton, Dickinson & Co.), the companies said, in a $17.5 billion deal that would be the year’s largest within life ...

Global medtech giant BD (Becton, Dickinson and Co.) announced today it has acquired Tepha Inc., a developer and manufacturer of proprietary resorbable polymer technology. Tepha's resorbable polymer ...

Becton Dickinson & Co. is set to make additional investments in its U.S. manufacturing network to add capacity for critical medical devices. “BD has a longstanding history as a leading U.S.